Incentive funding awards reduced to find money to cover gaps in countries with shortened grant durations, TRP says
According to the Technical Review Panel (TRP), incentive funding recommendations for components submitted in Window 4 were reduced because the Secretariat “saw no other option to cover gaps for countries with shortened grant durations”. The gaps refer to the period between the end of the shortened grants and December 2017, after which funding from the next replenishment should become available.
Neither the Global Fund Secretariat nor Ethiopia have the necessary systems in place to allow for a national financing strategy model to be implemented at this time. This is the conclusion of a pre-implementation review commissioned by the Secretariat and conducted by the Office of the Inspector General (OIG). The review was conducted between September and November 2014. A report on the review was released on 25 February 2015.
The Technical Review Panel (TRP) has released its most comprehensive report yet on the quality and scope of concept notes submitted under the Global Fund's new funding model (NFM), drawing conclusions and identifying trends in the 91 proposals submitted during windows 3 and 4.
David Garmaise opens his commentary with an accurate observation: He had a misperception. But he arrives at a conclusion that is wrong. The consequences of the new funding model were not, in fact, unanticipated.
For nearly a decade, China was one of the largest recipients of grants from the Global Fund for its fight against AIDS, TB and malaria. From 2003-2012, more than $805 million was disbursed to support 15 grants, nearly half of which (46%) contributed to prevention, diagnosis and treatment campaigns for TB across the country.
Cuando el Fondo Mundial de Lucha contra el SIDA , la tuberculosis y la malaria fue creado en 2002, su objetivo era proporcionar apoyo financiero a los países en desarrollo en su lucha contra tres enfermedades transmisibles sin fronteras para las que opciones de tratamiento y de prevención estaban disponibles.
The Global Fund Board has decided that the Affordable Medicines Facility-malaria (AMFm) programme will not continue as a stand-alone programme, but elements will be retained and integrated into the core funding system. The decision was made at the 28th Global Fund Board meeting held in Geneva on 14th and 15th of November.